Bank of New York Mellon Corp Sells 8,266 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bank of New York Mellon Corp lessened its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 170,481 shares of the medical instruments supplier's stock after selling 8,266 shares during the quarter. Bank of New York Mellon Corp owned 0.75% of LeMaitre Vascular worth $14,303,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of LMAT. Raymond James Financial Inc. acquired a new position in LeMaitre Vascular during the fourth quarter worth $14,900,000. Rockefeller Capital Management L.P. acquired a new stake in shares of LeMaitre Vascular in the fourth quarter valued at about $7,787,000. Segall Bryant & Hamill LLC acquired a new stake in shares of LeMaitre Vascular in the fourth quarter valued at about $5,446,000. Invesco Ltd. grew its position in shares of LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock valued at $16,124,000 after purchasing an additional 58,720 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of LeMaitre Vascular by 7,486.5% in the first quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock valued at $4,519,000 after purchasing an additional 53,154 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

LMAT stock traded up $0.05 during trading on Monday, reaching $79.82. 102,976 shares of the stock were exchanged, compared to its average volume of 168,922. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The company has a market capitalization of $1.80 billion, a P/E ratio of 40.31, a price-to-earnings-growth ratio of 2.10 and a beta of 0.82. The stock has a 50 day simple moving average of $82.82 and a 200-day simple moving average of $87.72. The company has a current ratio of 16.49, a quick ratio of 13.83 and a debt-to-equity ratio of 0.48.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. The firm's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.44 earnings per share. As a group, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 1.00%. The ex-dividend date was Thursday, May 15th. LeMaitre Vascular's dividend payout ratio (DPR) is presently 40.40%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 76,868 shares of the company's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the sale, the chief executive officer owned 1,796,783 shares in the company, valued at approximately $154,146,013.57. The trade was a 4.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 100,000 shares of company stock valued at $8,556,857. Insiders own 9.50% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.